Delcath Systems, Inc. (NASDAQ: DCTH), a specialty pharmaceutical and medical device company focused on treatment of primary and metastatic liver cancers, announces that the Company's new website for European patient education - www.againsttheodds.eu - has been awarded a silver medal in the Biannual Digital Health Awards.
The website was developed as an education and support resource for European patients and their families who are coping with the devastating diagnosis of cancer in the liver. The site provides patient-friendly content and videos that clearly explain the different types of liver cancers as well as the tests and screening tools used in the diagnosis process. The www.againsttheodds.eu site also provides advice for general health and well-being for patients undergoing liver cancer treatment, and information on treatment options including the Delcath Hepatic CHEMOSAT® Delivery System.
The silver award from Digital Health recognizes high-quality consumer health information based on content, format and success in reaching the targeted audience.
CHEMOSAT is currently marketed in Europe as a device under the trade name Delcath Hepatic CHEMOSAT® Delivery System for Melphalan (CHEMOSAT). In the U.S. the Melphalan/HDS system is considered a combination drug and device product, and is regulated as a drug by the U.S. Food and Drug Administration (FDA). Melphalan/HDS has not been approved for sale in the U.S. and is currently being investigated in a Phase 3 clinical trial as a treatment for hepatic dominant ocular melanoma.
"We hope that www.againsttheodds.eu and its German language companion site www.lebengewinnen.deempower European patients with knowledge about their disease and informs them of the various treatment options available," said Jennifer K. Simpson, Ph.D., MSN, CRNP, President and Chief Executive Office of Delcath Systems. "These sites were developed and launched as part of an ongoing overhaul of our internet presence in support of European commercialization and our Clinical Development Program, and we expect to launch additional redesigns of our web properties in the coming months."
About Delcath Systems
Delcath Systems, Inc. is a specialty pharmaceutical and medical device company focused on oncology with a principal focus on the treatment of primary and metastatic liver cancers. Our proprietary Melphalan Hydrochloride for Injection for use with the Delcath Hepatic Delivery System (Melphalan/HDS) is designed to administer high-dose chemotherapy to the liver while controlling systemic exposure. In April 2012 we obtained authorization to affix a CE Mark to our second-generation system, which is currently marketed in Europe as a device under the trade name Delcath Hepatic CHEMOSAT® Delivery System for Melphalan (CHEMOSAT). In the U.S. the Melphalan/HDS system is considered a combination drug and device product, and is regulated as a drug by the U.S. Food and Drug Administration (FDA). Melphalan/HDS has not been approved for sale in the U.S. We have commenced our global Phase 3 FOCUS clinical trial for Patients with Hepatic Dominant Ocular Melanoma (OM) and a global Phase 2 clinical trial in Europe and the U.S. to investigate the Melphalan/HDS system for the treatment of primary liver cancer (HCC) and intrahepatic cholangiocarcinoma (ICC).
